Positions for La Jolla Pharmaceutical Co (NASDAQ:LJPC)

“Big money sentiment for La Jolla Pharmaceutical Co (NASDAQ:LJPC) in Q4 2018 increased to 1.48, SEC filings reveal. That’s up 0.25, from 2018Q3’s 1.23. 43 investment professionals increased and opened new equity positions, while 29 decreased and sold stakes in La Jolla Pharmaceutical Co so the sentiment is better. Funds own 30.80 million shares, down from 32.70 million shares in 2018Q3. Funds holding La Jolla Pharmaceutical Co in top 10 changed to 1 from 4 for a decrease of 3. In total 11 funds closed positions, 18 reduced and 23 increased. Also 20 funds bought new La Jolla Pharmaceutical Co stakes.

Biggest La Jolla Pharmaceutical Co Investors

As of Q4 2018 Tang Capital Management Llc has 8.39% invested in La Jolla Pharmaceutical Co. As of Q4 2018, 1.95 million shares of La Jolla Pharmaceutical Co are owned by Broadfin Capital Llc. Sectoral Asset Management Inc reported 1.76 million shares. Perceptive Advisors Llc revealed 4.31 million shares position in La Jolla Pharmaceutical Co. The Georgia-based fund Emory University holds 149,013 shares or 1.11% of their US long stock exposure.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases.The firm is worth $183.04 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome.Currently it has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

LJPC is touching $6.76 during the last trading session, after decreased 4.65%.La Jolla Pharmaceutical Company has volume of 691,096 shares. Since March 22, 2018 LJPC has declined 79.47% and is downtrending. The stock underperformed the S&P 500 by 83.84%.

Cubist Systematic Strategies Ltd Liability Com reported 0% stake. 31,900 are held by California Pub Employees Retirement Sys. The Quebec – Canada-based Sectoral Asset Management Inc has invested 2.26% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Tang Management Ltd Llc has 8.39% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 3.88M shs. Swiss Comml Bank reported 34,800 shs or 0% of all its holdings. Fosun Limited invested in 0.18% or 308,650 shs. State Street Corporation holds 407,397 shs or 0% of its capital. Credit Suisse Ag reported 15,637 shs. National Bank Of New York Mellon invested in 0% or 85,150 shs. Millennium Mgmt Ltd Liability Corporation invested in 490,273 shs or 0.01% of the stock. Meeder Asset reported 0% stake. Int Group Inc Inc owns 14,117 shs for 0% of their capital. Charles Schwab Invest Mngmt holds 114,809 shs. Spark Invest Ltd Liability Corporation holds 122,995 shs or 0.08% of its capital. 165,700 are owned by Highland Capital Ltd Partnership.

La Jolla Pharmaceutical Company had 1 sale and 5 insider buys since January 7, 2019. This’s net activity of $4.66 million. Chawla Lakhmir S bought 3,000 shs worth $16,694. On Wednesday, January 9 1,600 shs were bought by Rolke James, worth $9,746. TANG KEVIN C bought $6.99M worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) or 1.30 million shs on Monday, January 7. 2.06M shs valued at $11.72M were sold by PERCEPTIVE ADVISORS LLC on Monday, January 7. CARVER JENNIFER also bought $30,825 worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) on Wednesday, January 9.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Total analysts of 4 have positions in La Jolla Pharmaceutical (NASDAQ:LJPC) as follows: 2 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 50%. Since January 14, 2019 according to StockzIntelligence Inc La Jolla Pharmaceutical has 5 analyst reports. On Wednesday, January 23 the firm earned “Neutral” rating by JP Morgan. On Tuesday, March 5 H.C. Wainwright maintained La Jolla Pharmaceutical Company (NASDAQ:LJPC) with “Buy” rating. The stock rating was upgraded by Jefferies to “Hold” on Monday, January 14. On Monday, March 4 the firm earned “Buy” rating by Cowen & Co.

For more La Jolla Pharmaceutical Company (NASDAQ:LJPC) news brought out recently go to: Nasdaq.com, Benzinga.com, Benzinga.com, 247Wallst.com or Globenewswire.com. The titles are as follows: “La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference – Nasdaq” brought out on March 07, 2019, “31 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” on February 21, 2019, “Earnings Scheduled For March 4, 2019 – Benzinga” with a publish date: March 04, 2019, “5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential – 24/7 Wall St.” and the last “La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA – GlobeNewswire” with publication date: August 03, 2018.